Transfusing Convalescent Plasma as Post-Exposure Prophylaxis Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Double-Blinded, Phase 2 Randomized, Controlled Trial

By sjmartinez • February 11, 2023

Shoham S, Bloch EM, Casadevall A, Hanley D, Lau B, Gebo K, Cachay E, Kassaye SG, Paxton JH, Gerber J, Levine AC, Naeim A, Currier J, Patel B, Allen ES, Anjan S, Appel L, Baksh S, Blair PW, Bowen A, Broderick P, Caputo CA, Cluzet V, Cordisco ME, Cruser D, Ehrhardt S, Forthal D, Fukuta Y, Gawad AL, Gniadek T, Hammel J, Huaman MA, Jabs DA, Jedlicka A, Karlen N, Klein S, Laeyendecker O, Lane K, McBee N, Meisenberg B, Merlo C, Mosnaim G, Park HS, Pekosz A, Petrini J, Rausch W, Shade DM, Shapiro JR, Singleton JR, Sutcliffe C, Thomas DL, Yarava A, Zand M, Zenilman JM, Tobian AAR, Sullivan DJ. Transfusing Convalescent Plasma as Post-Exposure Prophylaxis Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Double-Blinded, Phase 2 Randomized, Controlled Trial. Clin Infect Dis. 2023 Feb 8;76(3):e477-e486. doi: 10.1093/cid/ciac372. PMID: 35579509; PMCID: PMC9129191.

Tags: convalescent plasma, covid-19, Infectious Diseases, post-exposure-prophylaxis, Publications, SARS-CoV-2, transfusion

Impact of antenatal screening for Chlamydia and Gonorrhea on pregnancy outcomes in South African women

Nyemba DC, de Voux A, Mvududu R, Peters RPH, Delany-Moretlwe S, Johnson LF, Coates TJ, Myer L, Davey DLJ. Impact of antenatal screening for Chlamydia[...]

Polygenic risk score and risk of drug-induced liver injury after initiating antiretroviral therapy in people living with HIV

Cindi Z, Cardone KM, Bradford Y, Hall MA, Kim H, Daar ES, Gulick R, Riddler SA, Vujkovic M, Chang KM, Tsao PS, Sinxadi P, Haas[...]

CMV Infection after Lung Transplant: incidence, risk factors and management in a multi-center cohort

Snyder LD, Weber JM, Avery R, Neely ML, Robien MA, Schaenman J, Tsuang WM, Weigt SS, Kumar D. CMV Infection after Lung Transplant: incidence, risk[...]